222 related articles for article (PubMed ID: 10229644)
1. Influence of the treatment protocol upon the in vivo efficacy of cidofovir (HPMPC) and of acyclovir (ACV) formulations in topical treatment of cutaneous HSV-1 infection in hairless mice.
Afouna MI; Mehta SC; Ghanem AH; Higuchi WI; Kern ER; DeClercq E; El-Shattawy HH
J Pharm Sci; 1999 May; 88(5):530-4. PubMed ID: 10229644
[TBL] [Abstract][Full Text] [Related]
2. Effect of Azone upon the in vivo antiviral efficacy of cidofovir or acyclovir topical formulations in treatment/prevention of cutaneous HSV-1 infections and its correlation with skin target site free drug concentration in hairless mice.
Afouna MI; Fincher TK; Zaghloul AA; Reddy IK
Int J Pharm; 2003 Mar; 253(1-2):159-68. PubMed ID: 12593946
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).
Snoeck R; Andrei G; Gérard M; Silverman A; Hedderman A; Balzarini J; Sadzot-Delvaux C; Tricot G; Clumeck N; De Clercq E
Clin Infect Dis; 1994 Apr; 18(4):570-8. PubMed ID: 8038312
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice.
De Clercq E; Holý A
Antimicrob Agents Chemother; 1991 Apr; 35(4):701-6. PubMed ID: 2069375
[TBL] [Abstract][Full Text] [Related]
5. Assessment of correlation between skin target site free drug concentration and the in vivo topical antiviral efficacy in hairless mice for (E)-5-(2-bromovinyl)-2'-deoxyuridine and acyclovir formulations.
Afouna MI; Mehta SC; Ghanem AH; Higuchi WI; Kern ER; De Clercq E; El-Shattawy HH
J Pharm Sci; 1998 Aug; 87(8):917-21. PubMed ID: 9687333
[TBL] [Abstract][Full Text] [Related]
6. Novel animal model for evaluating topical efficacy of antiviral agents: flux versus efficacy correlations in the acyclovir treatment of cutaneous herpes simplex virus type 1 (HSV-1) infections in hairless mice.
Lee PH; Su MH; Kern ER; Higuchi WI
Pharm Res; 1992 Aug; 9(8):979-89. PubMed ID: 1329068
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of HPMPC therapy for primary and recurrent genital herpes in mice and guinea pigs.
Bravo FJ; Stanberry LR; Kier AB; Vogt PE; Kern ER
Antiviral Res; 1993 May; 21(1):59-72. PubMed ID: 8391249
[TBL] [Abstract][Full Text] [Related]
8. Correlation of in vivo topical efficacies with in vitro predictions using acyclovir formulations in the treatment of cutaneous HSV-1 infections in hairless mice: an evaluation of the predictive value of the C* concept.
Patel PJ; Ghanem AH; Higuchi WI; Srinivasan V; Kern ER
Antiviral Res; 1996 Mar; 29(2-3):279-86. PubMed ID: 8739606
[TBL] [Abstract][Full Text] [Related]
9. Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model.
Romanowski EG; Bartels SP; Gordon YJ
Invest Ophthalmol Vis Sci; 1999 Feb; 40(2):378-84. PubMed ID: 9950596
[TBL] [Abstract][Full Text] [Related]
10. Relationship of skin target site free drug concentration (C*) to the in vivo efficacy: an extensive evaluation of the predictive value of the C* concept using acyclovir as a model drug.
Mehta SC; Afouna MI; Ghanem AH; Higuchi WI; Kern ER
J Pharm Sci; 1997 Jul; 86(7):797-801. PubMed ID: 9232519
[TBL] [Abstract][Full Text] [Related]
11. Management of acyclovir-resistant herpes simplex virus.
Chilukuri S; Rosen T
Dermatol Clin; 2003 Apr; 21(2):311-20. PubMed ID: 12757254
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections.
De Clercq E
Verh K Acad Geneeskd Belg; 1996; 58(1):19-47; discussion 47-9. PubMed ID: 8701600
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of cutaneous human papilloma virus, poxvirus and herpes simplex virus infections with topical cidofovir in HIV positive patients].
Toutous-Trellu L; Hirschel B; Piguet V; Schiffer V; Saurat JH; Pechère M
Ann Dermatol Venereol; 2004 May; 131(5):445-9. PubMed ID: 15235531
[TBL] [Abstract][Full Text] [Related]
14. Topical treatment of cutaneous vaccinia virus infections in immunosuppressed hairless mice with selected antiviral substances.
Smee DF; Bailey KW; Wong MH; Tarbet EB
Antivir Chem Chemother; 2011 May; 21(5):201-8. PubMed ID: 21566266
[TBL] [Abstract][Full Text] [Related]
15. Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice.
Smee DF; Bailey KW; Wong MH; Wandersee MK; Sidwell RW
J Infect Dis; 2004 Sep; 190(6):1132-9. PubMed ID: 15319864
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of HIV-infected patients once diagnosed with acyclovir-resistant herpes simplex virus infection.
Seang S; Boutolleau D; Burrel S; Regnier S; Epelboin L; Voujon D; Valantin MA; Katlama C; Agut H; Caumes E
Int J STD AIDS; 2014 Aug; 25(9):676-82. PubMed ID: 24535691
[TBL] [Abstract][Full Text] [Related]
17. Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS.
Lalezari JP; Drew WL; Glutzer E; Miner D; Safrin S; Owen WF; Davidson JM; Fisher PE; Jaffe HS
J Infect Dis; 1994 Sep; 170(3):570-2. PubMed ID: 8077713
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Herpes simplex virus infections with topical antiviral agents.
Hamuy R; Berman B
Eur J Dermatol; 1998; 8(5):310-9. PubMed ID: 9683881
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine.
Bronson JJ; Ghazzouli I; Hitchcock MJ; Webb RR; Martin JC
J Med Chem; 1989 Jul; 32(7):1457-63. PubMed ID: 2544723
[TBL] [Abstract][Full Text] [Related]
20. A review of topical and intralesional cidofovir.
Zabawski EJ
Dermatol Online J; 2000 Sep; 6(1):3. PubMed ID: 11328613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
